{"id":"https://openalex.org/W2053138570","doi":"https://doi.org/10.5414/cpp46273","title":"Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study","display_name":"Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study","alternate_titles":[],"publication_year":2008,"publication_date":"2008-06-01","ids":{"openalex":"https://openalex.org/W2053138570","doi":"https://doi.org/10.5414/cpp46273","mag":"2053138570","pmid":"https://pubmed.ncbi.nlm.nih.gov/18541123"},"language":"en","primary_location":{"id":"doi:10.5414/cpp46273","doi":"https://doi.org/10.5414/cpp46273","is_oa":false,"landing_page_url":"https://doi.org/10.5414/cpp46273","pdf_url":null,"source":{"id":"https://openalex.org/S166536441","display_name":"International Journal of Clinical Pharmacology and Therapeutics","issn_l":"0946-1965","issn":["0946-1965"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","jufo-1","medline","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310313675","host_organization_name":"Dustri-Verlag","host_organization_lineage":["https://openalex.org/P4310313675"],"host_organization_lineage_names":["Dustri-Verlag"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Int. Journal of Clinical Pharmacology and Therapeutics","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2053138570"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5108989698","display_name":"S. Irie","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115738","display_name":"SOUSEIKAI Global Clinical Research Center","ror":"https://ror.org/022bpxw56","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210115738"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"S. Irie","raw_affiliation_strings":["Kyushu Clinical Pharmacology Research Clinic, Fukuoka, Japan. shin-irie@lta-med.com"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kyushu Clinical Pharmacology Research Clinic, Fukuoka, Japan. shin-irie@lta-med.com","institution_ids":["https://openalex.org/I4210115738"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028273614","display_name":"Yasuhiro Matsumura","orcid":"https://orcid.org/0000-0003-4331-8177","observed_orcids":["https://orcid.org/0000-0003-4331-8177"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Y. Matsumura","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"M. Zdravkovic","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"M. Zdravkovic","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112171221","display_name":"Lisbeth Vesterg\u00e5rd Jacobsen","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"L.V. Jacobsen","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5112176608","display_name":"Shigeru Kageyama","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"S. Kageyama","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":4.6439,"has_fulltext":false,"cited_by_count":39,"citation_normalized_percentile":{"value":0.95292958,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":86,"max":95},"biblio":{"volume":"46","issue":"06","first_page":"273","last_page":"279"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":0.0017999999690800905,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/liraglutide","display_name":"liraglutide","score":1.0},{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.9120000004768372},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.8849999904632568},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8560000061988831},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":1.0},{"id":"https://openalex.org/keywords/tolerability","display_name":"tolerability","score":0.8539999723434448},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.7789999842643738},{"id":"https://openalex.org/keywords/subcutaneous-administration","display_name":"subcutaneous administration","score":0.8650000095367432},{"id":"https://openalex.org/keywords/hypoglycemia","display_name":"hypoglycemia","score":0.847000002861023},{"id":"https://openalex.org/keywords/postprandial-blood-glucose","display_name":"postprandial blood glucose","score":0.7829999923706055},{"id":"https://openalex.org/keywords/weight-loss","display_name":"weight loss","score":0.7940000295639038}],"concepts":[{"id":"https://openalex.org/C2781308992","wikidata":"https://www.wikidata.org/wiki/Q2526479","display_name":"Liraglutide","level":4,"score":0.9738057851791382},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.8235154151916504},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8131561279296875},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7820970416069031},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.7361211776733398},{"id":"https://openalex.org/C2778199505","wikidata":"https://www.wikidata.org/wiki/Q2992990","display_name":"Postprandial","level":3,"score":0.6343663930892944},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.5918064117431641},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5144093632698059},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.4581640362739563},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4327234625816345},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4246964752674103},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.33662551641464233},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.32039880752563477},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000069450","descriptor_name":"Liraglutide","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001786","descriptor_name":"Blood Glucose","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006207","descriptor_name":"Half-Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D007279","descriptor_name":"Injections, Subcutaneous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007564","descriptor_name":"Japan","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014018","descriptor_name":"Tissue Distribution","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015431","descriptor_name":"Weight Loss","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D052216","descriptor_name":"Glucagon-Like Peptide 1","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D052216","descriptor_name":"Glucagon-Like Peptide 1","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D052216","descriptor_name":"Glucagon-Like Peptide 1","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D052216","descriptor_name":"Glucagon-Like Peptide 1","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.5414/cpp46273","doi":"https://doi.org/10.5414/cpp46273","is_oa":false,"landing_page_url":"https://doi.org/10.5414/cpp46273","pdf_url":null,"source":{"id":"https://openalex.org/S166536441","display_name":"International Journal of Clinical Pharmacology and Therapeutics","issn_l":"0946-1965","issn":["0946-1965"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","jufo-1","medline","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310313675","host_organization_name":"Dustri-Verlag","host_organization_lineage":["https://openalex.org/P4310313675"],"host_organization_lineage_names":["Dustri-Verlag"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Int. Journal of Clinical Pharmacology and Therapeutics","raw_type":"journal-article"},{"id":"pmid:18541123","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/18541123","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International journal of clinical pharmacology and therapeutics","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/randomized-controlled-trial","display_name":"Randomized Controlled Trial"},{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2149042564","https://openalex.org/W2043092889","https://openalex.org/W2012425163","https://openalex.org/W2161671847","https://openalex.org/W2150641192","https://openalex.org/W2167934167","https://openalex.org/W2126674572","https://openalex.org/W2076851249","https://openalex.org/W2042822582","https://openalex.org/W2085673400"],"abstract_inverted_index":{"OBJECTIVES:":[0],"Liraglutide":[1,175,243],"is":[2,44],"a":[3,11,230,267],"once-daily":[4,63],"human":[5],"GLP-1":[6],"analog":[7],"being":[8],"developed":[9],"as":[10],"Type":[12,23],"2":[13,24,96],"diabetes":[14,25],"therapy.":[15],"A":[16],"dose-finding":[17],"study":[18,144],"in":[19,32,50,88,179,211,238,256,263],"Japanese":[20,53,257],"patients":[21],"with":[22,39,155,219,236,275],"showed":[26,176],"liraglutide":[27,43,66,106,237],"to":[28,85,115,134,234,240,245,253],"produce":[29],"dose-dependent":[30,177,209],"decreases":[31,210],"HbA(1C).":[33],"Studies":[34],"have":[35],"also":[36],"shown":[37],"that,":[38],"stepped":[40,76,108],"dose":[41,104],"titration,":[42],"well":[45,247],"tolerated.":[46],"This":[47],"double-blind":[48],"trial":[49],"24":[51],"healthy":[52],"men":[54],"assessed":[55],"the":[56,75,130,143,150,153,180],"safety,":[57],"tolerability,":[58],"pharmacokinetics":[59],"and":[60,73,95,117,136,187,192,213],"pharmacodynamics":[61],"of":[62,90,105,152,183,251],"subcutaneous":[64],"(s.c.)":[65],"using":[67,74],"doses":[68,250],"exceeding":[69],"those":[70],"previously":[71],"studied,":[72],"titration":[77],"approach.":[78],"MATERIALS":[79],"AND":[80],"METHODS:":[81],"Subjects":[82,140],"were":[83,173,194,200,217],"randomized":[84],"three":[86],"groups":[87,205],"each":[89],"which":[91],"6":[92],"received":[93],"liraglutide,":[94,220],"placebo":[97],"for":[98,232,270],"35":[99],"consecutive":[100],"days.":[101],"The":[102],"daily":[103],"was":[107,229,272],"from":[109,146],"5":[110],"microg/kg":[111,120,255],"(s.c.":[112],"abdomen,":[113],"morning)":[114],"10":[116],"then":[118],"15":[119],"at":[121,127,142,206,249],"7-day":[122],"intervals.":[123],"One":[124],"group":[125],"remained":[126,141,224],"this":[128,264],"dose,":[129],"others":[131],"titrating":[132],"further":[133],"20":[135],"25":[137,254],"microg/kg,":[138],"respectively.":[139],"site":[145],"Day":[147],"21":[148],"until":[149],"end":[151],"trial,":[154],"standard":[156],"meals":[157],"served":[158],"during":[159],"inhouse":[160],"periods.":[161],"RESULTS:":[162],"No":[163],"safety":[164],"issues,":[165],"hypoglycemia,":[166],"gastrointestinal":[167,277],"or":[168],"any":[169],"other":[170],"adverse":[171],"events":[172],"observed.":[174],"increases":[178],"pharmacokinetic":[181],"parameters":[182],"AUC0-24":[184],"h,":[185],"C(max)":[186],"C(trough),":[188],"while":[189],"t(max),":[190],"t(1/2)":[191],"V(d/F)":[193],"constant.":[195],"Mean":[196],"plasma":[197,215],"glucose":[198,216],"concentrations":[199],"similar":[201],"across":[202],"all":[203,222],"treatment":[204],"baseline,":[207],"but":[208],"mean":[212],"postprandial":[214],"seen":[218],"although":[221],"values":[223],"within":[225],"normal":[226],"ranges.":[227],"There":[228],"tendency":[231],"weight":[233],"decrease":[235],"comparison":[239],"placebo.":[241],"CONCLUSIONS:":[242],"appears":[244],"be":[246],"tolerated":[248],"up":[252],"subjects.":[258],"Despite":[259],"clear":[260],"pharmacodynamic":[261],"effects":[262],"euglycemic":[265],"cohort,":[266],"low":[268],"risk":[269],"hypoglycemia":[271],"suggested":[273],"together":[274],"good":[276],"tolerability.":[278]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2053138570","counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2021,"cited_by_count":1},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":1},{"year":2012,"cited_by_count":2}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
